Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2024 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
December 12, 2023 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings ...
December 08, 2023 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
November 28, 2023 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

Onconova presenting at NobleCon19 Dec 4-5 in Boca Raton, FL
November 14, 2023 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
November 07, 2023 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
November 02, 2023 10:37 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE...
October 24, 2023 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Expands Leadership Team with Two Key Appointments

Onconova Expands Leadership Team: Victor Moyo named Chief Medical Officer, Meena Arora joins as Vice President Global Medical Affairs and R&D
October 19, 2023 08:00 ET | Source: Onconova Therapeutics, Inc.

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023Additional studies support broad potential, especially in cyclin-dependent cancers NEWTOWN, Pa., Oct. 19, 2023 (GLOBE...
October 12, 2023 08:00 ET | Source: Onconova Therapeutics, Inc.

Encouraging Rigosertib Data Presented at EADV as Late Breaker

NEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on...